ATE390435T1 - Zusammensetzungen und verfahren zur diagnose und behandlung von diabetes, insulinresistenz und dyslipidämie - Google Patents

Zusammensetzungen und verfahren zur diagnose und behandlung von diabetes, insulinresistenz und dyslipidämie

Info

Publication number
ATE390435T1
ATE390435T1 AT02795910T AT02795910T ATE390435T1 AT E390435 T1 ATE390435 T1 AT E390435T1 AT 02795910 T AT02795910 T AT 02795910T AT 02795910 T AT02795910 T AT 02795910T AT E390435 T1 ATE390435 T1 AT E390435T1
Authority
AT
Austria
Prior art keywords
methods
diabetes
dyslipidemia
insulin resistance
compositions
Prior art date
Application number
AT02795910T
Other languages
English (en)
Inventor
Steve Waters
Shonna Moodie
Brian Lavan
Thomas Gustafson
Original Assignee
Metabolex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabolex Inc filed Critical Metabolex Inc
Application granted granted Critical
Publication of ATE390435T1 publication Critical patent/ATE390435T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/88—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving prostaglandins or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT02795910T 2001-12-17 2002-12-16 Zusammensetzungen und verfahren zur diagnose und behandlung von diabetes, insulinresistenz und dyslipidämie ATE390435T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34145101P 2001-12-17 2001-12-17

Publications (1)

Publication Number Publication Date
ATE390435T1 true ATE390435T1 (de) 2008-04-15

Family

ID=23337630

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02795910T ATE390435T1 (de) 2001-12-17 2002-12-16 Zusammensetzungen und verfahren zur diagnose und behandlung von diabetes, insulinresistenz und dyslipidämie

Country Status (8)

Country Link
US (1) US7510851B2 (de)
EP (1) EP1465911B1 (de)
JP (1) JP2005520497A (de)
AT (1) ATE390435T1 (de)
AU (1) AU2002360637B2 (de)
CA (1) CA2470431A1 (de)
DE (1) DE60225845D1 (de)
WO (1) WO2003051182A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7054758B2 (en) * 2001-01-30 2006-05-30 Sciona Limited Computer-assisted means for assessing lifestyle risk factors
WO2007127965A1 (en) 2006-04-28 2007-11-08 Mayo Foundation For Medical Education And Research Treating glaucoma, cardiovascular diseases, and renal diseases
JP5283106B2 (ja) * 2008-03-14 2013-09-04 国立大学法人 熊本大学 C型肝炎ウイルス阻害剤
JP6023045B2 (ja) * 2010-05-27 2016-11-09 ファルマツェル、ゲーエムベーハー 新規7α−ヒドロキシステロイドデヒドロゲナーゼノックアウト突然変異体およびその使用
AU2021431102A1 (en) * 2021-03-05 2023-09-21 Ascentawits Pharmaceuticals, Ltd. Primer-probe composition, kit, and detection method

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60142984A (ja) * 1983-12-28 1985-07-29 Kyorin Pharmaceut Co Ltd 新規なスピロピロリジン−2,5−ジオン誘導体およびその製造法
US6124115A (en) 1995-09-22 2000-09-26 Endorecherche Inc. Production and use of isolated type 5 17β-hydroxysteroid dehydrogenase
US5756299A (en) * 1996-12-09 1998-05-26 Incyte Pharmaceuticals, Inc. Human carbonyl reductase
US6001353A (en) * 1997-05-09 1999-12-14 The Board Of Trustees Of The Univeristy Of Illinois 20α-alpha-hydroxy steroid dehydrogenase related material and methods
ES2330062T3 (es) * 1998-05-06 2009-12-03 Metamorphix, Inc. Procedimientos para tratar la diabetes por inhibicion de gdf-8.
WO2001079223A2 (en) 2000-04-12 2001-10-25 Genaissance Pharmaceuticals, Inc. Haplotypes of the akr1b1 gene
AU2002245214A1 (en) * 2001-01-04 2002-07-16 Myriad Genetics, Inc. Protein-protein interactions
KR100423912B1 (ko) 2001-05-04 2004-03-24 삼성전자주식회사 씨모스형 반도체 장치 형성 방법

Also Published As

Publication number Publication date
JP2005520497A (ja) 2005-07-14
EP1465911B1 (de) 2008-03-26
DE60225845D1 (de) 2008-05-08
US7510851B2 (en) 2009-03-31
EP1465911A4 (de) 2006-04-19
CA2470431A1 (en) 2003-06-26
US20030186871A1 (en) 2003-10-02
WO2003051182A2 (en) 2003-06-26
AU2002360637A1 (en) 2003-06-30
EP1465911A2 (de) 2004-10-13
WO2003051182A3 (en) 2004-08-12
AU2002360637B2 (en) 2007-08-30

Similar Documents

Publication Publication Date Title
ATE440536T1 (de) Verfahren zur diagnose, behandlung und prävention von knochenverlust
ATE488251T1 (de) Verfahren zur diagnose und behandlung von schwangerschaftsskomplikationen
BR0111125A (pt) Moléculas de ácido nucléico de nrg-2, polipeptìdeos, e métodos diagnóstico e terapêuticos
ATE453653T1 (de) Platinkomplexe zur behandlung von tumoren
ATE321570T1 (de) Verfahren zur behandlung von hämostatischen störungen durch lösliches p-selectin
ATE466014T1 (de) Spiroazacyclische verbindungen als monoaminrezeptormodulatoren
ATE536855T1 (de) Gewebegerüste zusamensetzungen zur behandlung von zahnerkrankungen
ATE528410T1 (de) Verfahren und zusammensetzungen zur diagnose von altersbedingter maculadegeneration
DE60329165D1 (de) Detektion und/oder beobachtung von synuclein-assoziierten krankheiten
DE60126248D1 (de) Verwendung von brustkrebs membranproteine für behandlung, prophylaxe und diagnose von brustkrebs
ATE356995T1 (de) Verfahren zur identifizierung von mitteln zur behandlung von diabetes
NO20072076L (no) VWFA og/eller ANT_IG holdige proteiner
ATE338142T1 (de) Methoden zur diagnose und behandlung von herzkrankheiten
ATE480641T1 (de) Zusammensetzungen, reagenzien, kits und verfahren für die diagnose und behandlung von fettleibigkeit und/oder diabetes
DE60225845D1 (de) Zusammensetzungen und verfahren zur diagnose und behandlung von diabetes, insulinresistenz und dyslipidämie
WO2006017171A3 (en) Methods of diagnosing & treating obesity, diabetes and insulin resistance
ATE393785T1 (de) Glykopeptide, deren herstellung und verwendung in der diagnose oder behandlung von multipler sklerose
EP1363528A4 (de) Verfahren zur diagnose und behandlung von herzerkrankungen
WO2003102161A3 (en) Methods of diagnosing & treating diabetes and insulin resistance
ATE363075T1 (de) Verfahren zur diagnose und behandlung von metastasen und dafür nützliche zusammensetzung
EP1370697A4 (de) Peroxiredoxin-arzneistoffe zur behandlung einer hiv-1-infektion und verfahren zu deren verwendung
CY1110278T1 (el) Μεθοδος διαλογης παραγοντων ικανων να θεραπευουν την παχυσαρκια
DE60135339D1 (de) Behandlungsverfahren unter verwendung von 17906 und dessen anwendungen
WO2006010051A3 (en) Methods of diagnosing & treating diabetes and insulin resistance
ATE516813T1 (de) Verfahren und verbindungen zur behandlung von diabetes

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties